However, NF-κB-specific drug inhibitors that target NF-κB subunits (SN-50/52, NBD), prevent NF-κB DNA binding (PBS-1068, parthenolide), or block IκBα degradation (IMD-0354, BAY-11-7082, PS-1145) have not yet translated to clinical trials for cancer [97]. This evidence concerns the gene NFKB1 and cancer.